Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer

New England Journal of Medicine

Volumn 351, Issue 10, 2004, Pages

  Fyles, Anthony W ^a,d   McCready, David R ^a   Manchul, Lee A ^a   Trudeau, Maureen E ^a   Merante, Patricia ^a   Pintilie, Melania ^a   Weir, Lorna M ^b   Olivotto, Ivo A ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Princess Margaret Hospital ^*

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; AGING; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ERYTHEMA; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; HOT FLUSH; HUMAN; HUMAN TISSUE; LUNG TUMOR; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SIDE EFFECT; SURVIVAL RATE; TUMOR VOLUME; UTERUS TUMOR; ANALYSIS OF VARIANCE; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROGNOSIS; RADIOTHERAPY; RISK FACTOR; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RADIOTHERAPY; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN;

EID: 4344707888     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040595     Document Type: Article

References (22)

1. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst 1996;88:1659-64.
2. Liljegen G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 1999;17:2326-33.
3. Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 1996;348:708-13.
4. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
5. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
6. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-9.
7. Holli K, Saaristo R, Isola J, Joensuu H, Hakama M. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer 2001;84:164-9.
8. McCready DR, Chapman JA, Hanna WM, et al. Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients. Ann Surg Oncol 2000;7:562-7.
9. Clark RM, McCulloch PB, Levine MN, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 1992;84:683-9.
10. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97. [Erratum, J Clin Oncol 2001;19:2583.]
11. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97. [Erratum, J Clin Oncol 2001;19:2583.]
12. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993;328:1587-91.
13. Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N, Nicoloau N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol 2002;20:4015-21. [Erratum, J Clin Oncol 2002;20:4727.]
14. Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N, Nicoloau N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol 2002;20:4015-21. [Erratum, J Clin Oncol 2002;20:4727.]
15. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001;91:Suppl 8:1679-87.
16. Fleming T. Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr 1990;3:Suppl 2:S82-S87.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Yap KP, McCready DR, Narod S, Manchul LA, Trudeau M, Fyles A. Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma. Cancer 2003;97:1369-75.
19. Rayan G, Dawson LA, Bezjak A, et al. Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:154-61.
20. McCormick B, Botnick M, Hunt M, Petrek J. Are the axillary lymph nodes treated by standard tangent breast fields? J Surg Oncol 2002;81:12-8.
21. Schlembach PJ, Buchholz TA, Koss MI, et al. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys 2001;51:671-8.
22. Nattinger AB, Hoffmann KG, Kneusel KT, Schapira MM. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet 2000;356:1148-53.